Premium
Activated platelets positively regulate RANKL‐mediated osteoclast differentiation
Author(s) -
Weicht Barbara,
Maitz Philipp,
Kandler Barbara,
Fischer Michael B.,
Watzek Georg,
Gruber Reinhard
Publication year - 2007
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.21360
Subject(s) - rankl , osteoclast , microbiology and biotechnology , chemistry , platelet , biology , immunology , activator (genetics) , biochemistry , receptor
Platelets induce osteoclastogenesis in total bone marrow cultures where hematopoietic cells can interact with stromal cells. Whether or not activated platelets directly act on hematopoietic cells to promote their differentiation into osteoclasts remains unknown. Here we report that platelet releasates (PRS) increase osteoclastogenesis in stroma‐depleted, macrophage colony‐stimulating factor (M‐CSF)‐dependent bone marrow cells when cultured in the presence of receptor activator of NF‐kappaB ligand (RANKL). The increased number of tartrate‐resistant acid phosphatase‐positive multinucleated cells (MNC) was paralleled by an enhanced transcription of osteoclast specific genes. Osteoclastogenesis was observed with hematopoietic cells previously depleted of B‐cells or T‐cells. Immunoprecipitation of transforming growth factor‐beta (TGF‐β) decreased the osteoclastogenic capacity of the PRS. PRS enhanced phosphorylation of Smad‐2, a downstream signaling mediator of TGF‐β. PRS increased phosphorylation of p38 and c‐Jun NH(2)‐terminal kinase (JNK), whereas only blocking of p38 but not JNK signaling suppressed osteoclastogenesis. These results suggest that activated platelets can enhance osteoclastogenesis by providing a source of TGF‐β and by activating osteoclastogenic signaling pathways. J. Cell. Biochem. 102: 1300–1307, 2007. © 2007 Wiley‐Liss, Inc.